Vaughn David J
Division of Hematology/Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA 19104-4283, USA.
Urol Clin North Am. 2007 May;34(2):171-7; abstract viii-ix. doi: 10.1016/j.ucl.2007.03.001.
Through a series of well-designed randomized clinical trials, the treatment of patients with cisplatin-based chemotherapy has evolved such that approximately 90% of patients who have good-risk metastatic germ cell tumor (GCT) will be cured of their disease. At present, first-line chemotherapy for patients who have good-risk metastatic GCT is three cycles of bleomycin/etoposide/cisplatin. An alternative to this is four cycles of etoposide/cisplatin. This article examines the progress that has been made in the development of chemotherapy for good-risk metastatic GCT and raises questions for further consideration and investigation.
通过一系列精心设计的随机临床试验，基于顺铂的化疗对患者的治疗方法已经得到改进，以至于大约90%低风险转移性生殖细胞肿瘤（GCT）患者的疾病能够被治愈。目前，低风险转移性GCT患者的一线化疗方案是博来霉素/依托泊苷/顺铂三个周期。另一种方案是依托泊苷/顺铂四个周期。本文探讨了低风险转移性GCT化疗发展过程中取得的进展，并提出了有待进一步思考和研究的问题。
